Company profile: AustinPx
1.1 - Company Overview
Company description
- Provider of formulation and processing technologies for drug manufacturing, offering KinetiSol Technology for amorphous solid dispersions, bioavailability enhancement via amorphous dispersions, particle size reduction and lipid delivery, dosage form development, rapid screening, phase-appropriate analytics, and oral drug product manufacturing for preclinical through Phase II.
Products and services
- Drug Product Manufacturing: Clinical-grade fabrication of oral dosage forms, supporting material supply from preclinical through Phase II clinical trials to advance candidate progression
- KinetiSol Technology: Custom-engineered process that creates amorphous solid dispersions to enhance bioavailability of poorly soluble drugs, improving performance of challenging compounds in development
- Bioavailability Enhancement Technologies: Modular platform encompassing amorphous dispersions, particle size reduction, and lipid delivery to improve drug solubility and absorption for poorly soluble candidates
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AustinPx
Oncodesign
HQ: France
Website
- Description: Provider of precision medicine-driven oncology preclinical CRO services and biopharmaceutical R&D, developing anticancer therapies and leveraging platforms such as Nanocyclix for selective kinase inhibitors and OncoSNIPER AI for resistant patient stratification. Pipeline includes OPM-101 (RIPK2, IBD), OPM-102 (RIPK2, inflammation-related tumors), and an LRRK2 program (Parkinson’s), plus the IMODI cluster for cancer models and microbiota studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncodesign company profile →
Antios Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for viral diseases, focused on developing an oral drug candidate for the potentially curative treatment of HBV infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antios Therapeutics company profile →
Cellipont
HQ: United States
Website
- Description: Provider of cell therapy CDMO services specializing in cell therapy development and small-to-large batch production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellipont company profile →
Birgi Mefar
HQ: Turkey
Website
- Description: Provider of contract manufacturing of sterile parenteral solutions and suspensions, filling into ampoules, vials, lyo vials, pre-filled syringes and blow-fill-seal containers; manufacturer of primary packaging producing empty ampoules and vials from clear and amber glass tubing; lab services for stability studies, analytical method and process validation with scale-up; cGMP blistering, labeling, track and trace; GMP cold chain storage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Birgi Mefar company profile →
Senn Chemicals
HQ: Switzerland
Website
- Description: Provider of peptide development and manufacturing services, spanning intermediates to CGMP API and supporting discovery through commercial production. In the peptide business since 1963, SENN offers expertise to optimize processes and streamline scale-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senn Chemicals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AustinPx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AustinPx
2.2 - Growth funds investing in similar companies to AustinPx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AustinPx
4.2 - Public trading comparable groups for AustinPx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →